Mesothelioma Stratified Therapy (MiST) : A Multi-drug Phase II Trial in Malignant Mesothelioma

Summary

MiST is a British Lung Foundation funded, University of Leicester Study, a multi-arm stratified therapy based clinical trial for patients with relapsed mesothelioma.

The goal of MiST is to enable acceleration of novel, effective personalised therapy as a basis for improving survival outcomes for patients with mesothelioma.

Conditions

• Mesothelioma, Malignant

Interventions

DRUG

Rucaparib

PARP inhibitor

DRUG

Abemaciclib

CDK4/6 inhibitor

DRUG

pembrolizumab & bemcentinib

PD1 checkpoint inhibitor, AXL inhibitor

DRUG

Atezolizumab & Bevacizumab

PDL1 checkpoint inhibitor, VEGF inhibitor

DRUG

Dostarlimab and Niraparib

IG Antibody, PARP Inhibitor

Sponsors & Collaborators

• British Lung Foundation

  collaborator OTHER

• Clovis Oncology, Inc.

  collaborator INDUSTRY

• Eli Lilly and Company

  collaborator INDUSTRY

• Merck Sharp & Dohme LLC

  collaborator INDUSTRY

• BerGenBio ASA

  collaborator INDUSTRY

• Roche Pharma AG

  collaborator INDUSTRY

• University Hospitals, Leicester

  collaborator OTHER

• The Christie NHS Foundation Trust

  collaborator OTHER

• GlaxoSmithKline

  collaborator INDUSTRY

• University of Leicester

  lead OTHER

Principal Investigators

• Dean Fennell, PhD, FRCP · University of Leicester

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

PARALLEL

Eligibility

Min Age

18 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2019-01-28

Primary Completion

2023-02-21

Completion

2024-03-15

Countries

• United Kingdom

Study Locations